Plain-English translation of NCT06063850 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This trial tests AMT-260, a new gene therapy designed to help people with a specific type of epilepsy called mesial temporal lobe epilepsy that hasn't responded well to anti-seizure medications. The treatment is given as a one-time procedure through the brain using special imaging guidance — no permanent brain removal is required. Researchers will carefully monitor your seizures and health to see if this medication reduces how often seizures occur and how much they affect your daily life.
Many people with this type of epilepsy continue to have frequent seizures even while taking multiple medications. This trial exists to test whether the medication can offer a new treatment option for people who haven't had success with standard anti-seizure drugs.
You likely qualify if…
You likely don't qualify if…
You will have one procedure where the medication is delivered directly into the affected part of your brain using MRI guidance and a special technique called convection-enhanced delivery — this is a one-time treatment, not repeated doses. After treatment, you'll come to study visits at the research center, have phone check-ins, provide blood tests, and keep an electronic diary of your seizures on your phone or computer. Researchers will ask you questions about how seizures are affecting your daily life, and you'll be closely monitored for safety over the study period.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States